Chronic inflammation is seen in a variety of diseases in both dogs and cats, including irritable bowel disease, chronic kidney disease, joint inflammatory conditions, and a wide variety of skin conditions such as atopic dermatitis. These can significantly impact quality-of-life and have symptoms distressing for both pet and their owner. There is evidence to demonstrate the involvement of TNF in canine atopic dermatitis, inflammatory bowel disease, and chronic kidney disease.
Tumor necrosis factor (TNF) is a protein involved with inflammation, which binds to its receptor protein (the TNF receptor) on the surface of cells, such as cells involved with immunity and inflammation. By binding to TNF, an ‘anti-TNF’ monoclonal antibody, or mAb, can prevent TNF from binding to its receptor. This results in a reduction of the effects of TNF in the body. Successful human therapies such as Enbrel®, Remicade® and Humira® use this approach to reducing inflammation.
Nexvet’s drug discovery team has identified new, potently neutralizing mAbs with high affinity for both canine and feline TNF, and these mAbs have been successfully PETized. These candidates are expected to have a half-life typical of mAbs that leads to a duration of action on the order of weeks in patients. Nexvet’s anti-TNF mAbs are progressing into proof-of-concept studies.